المؤلفون: Malcolm P. Huestis (10493092), Darlene Dela Cruz (10493095), Antonio G. DiPasquale (1274730), Matthew R. Durk (7052600), Charles Eigenbrot (1346406), Paul Gibbons (114343), Alberto Gobbi (1508113), Thomas L. Hunsaker (3160575), Hank La (438084), Dennis H. Leung (2106256), Wendy Liu (2057074), Shiva Malek (1346394), Mark Merchant (282025), John G. Moffat (413533), Christine S. Muli (10493098), Christine J. Orr (10493101), Brendan T. Parr (2342548), Frances Shanahan (655624), Christopher J. Sneeringer (10493104), Weiru Wang (640332), Ivana Yen (1346373), Jianping Yin (557395), Michael Siu (1503160), Joachim Rudolph (1464982)

مصطلحات موضوعية: Biophysics, Biochemistry, Medicine, Cell Biology, Molecular Biology, Pharmacology, Cancer, Hematology, Infectious Diseases, Virology, Space Science, Chemical Sciences not elsewhere classified, Physical Sciences not elsewhere classified, kinase selectivity, vivo evaluation, solubility, Combination Treatment, MEK inhibitor cobimetinib, tumor growth inhibition, NH functionality, pathway inhibition, Strategic substitution, fluoroquinazolinone hinge-binding motif, xenograft mouse model, C 5 position, RAF-specific residue interactions, aryl urea RAF inhibitors, type II pan-RAF inhibitor GNE -0749, Targeting KRAS Mutant Cancers

العلاقة: https://figshare.com/articles/journal_contribution/Targeting_KRAS_Mutant_Cancers_via_Combination_Treatment_Discovery_of_a_5_Fluoro-4-_3_i_H_i_quinazolinone_Aryl_Urea_pan-RAF_Kinase_Inhibitor/14336953Test

الإتاحة: https://doi.org/10.1021/acs.jmedchem.0c02085.s004Test

المؤلفون: Malcolm P. Huestis (10493092), Darlene Dela Cruz (10493095), Antonio G. DiPasquale (1274730), Matthew R. Durk (7052600), Charles Eigenbrot (1346406), Paul Gibbons (114343), Alberto Gobbi (1508113), Thomas L. Hunsaker (3160575), Hank La (438084), Dennis H. Leung (2106256), Wendy Liu (2057074), Shiva Malek (1346394), Mark Merchant (282025), John G. Moffat (413533), Christine S. Muli (10493098), Christine J. Orr (10493101), Brendan T. Parr (2342548), Frances Shanahan (655624), Christopher J. Sneeringer (10493104), Weiru Wang (640332), Ivana Yen (1346373), Jianping Yin (557395), Michael Siu (1503160), Joachim Rudolph (1464982)

مصطلحات موضوعية: Biophysics, Biochemistry, Medicine, Cell Biology, Molecular Biology, Pharmacology, Cancer, Hematology, Infectious Diseases, Virology, Space Science, Chemical Sciences not elsewhere classified, Physical Sciences not elsewhere classified, kinase selectivity, vivo evaluation, solubility, Combination Treatment, MEK inhibitor cobimetinib, tumor growth inhibition, NH functionality, pathway inhibition, Strategic substitution, fluoroquinazolinone hinge-binding motif, xenograft mouse model, C 5 position, RAF-specific residue interactions, aryl urea RAF inhibitors, type II pan-RAF inhibitor GNE -0749, Targeting KRAS Mutant Cancers

العلاقة: https://figshare.com/articles/dataset/Targeting_KRAS_Mutant_Cancers_via_Combination_Treatment_Discovery_of_a_5_Fluoro-4-_3_i_H_i_quinazolinone_Aryl_Urea_pan-RAF_Kinase_Inhibitor/14336944Test

الإتاحة: https://doi.org/10.1021/acs.jmedchem.0c02085.s001Test

المؤلفون: Malcolm P. Huestis (10493092), Darlene Dela Cruz (10493095), Antonio G. DiPasquale (1274730), Matthew R. Durk (7052600), Charles Eigenbrot (1346406), Paul Gibbons (114343), Alberto Gobbi (1508113), Thomas L. Hunsaker (3160575), Hank La (438084), Dennis H. Leung (2106256), Wendy Liu (2057074), Shiva Malek (1346394), Mark Merchant (282025), John G. Moffat (413533), Christine S. Muli (10493098), Christine J. Orr (10493101), Brendan T. Parr (2342548), Frances Shanahan (655624), Christopher J. Sneeringer (10493104), Weiru Wang (640332), Ivana Yen (1346373), Jianping Yin (557395), Michael Siu (1503160), Joachim Rudolph (1464982)

مصطلحات موضوعية: Biophysics, Biochemistry, Medicine, Cell Biology, Molecular Biology, Pharmacology, Cancer, Hematology, Infectious Diseases, Virology, Space Science, Chemical Sciences not elsewhere classified, Physical Sciences not elsewhere classified, kinase selectivity, vivo evaluation, solubility, Combination Treatment, MEK inhibitor cobimetinib, tumor growth inhibition, NH functionality, pathway inhibition, Strategic substitution, fluoroquinazolinone hinge-binding motif, xenograft mouse model, C 5 position, RAF-specific residue interactions, aryl urea RAF inhibitors, type II pan-RAF inhibitor GNE -0749, Targeting KRAS Mutant Cancers

العلاقة: https://figshare.com/articles/dataset/Targeting_KRAS_Mutant_Cancers_via_Combination_Treatment_Discovery_of_a_5_Fluoro-4-_3_i_H_i_quinazolinone_Aryl_Urea_pan-RAF_Kinase_Inhibitor/14336947Test

الإتاحة: https://doi.org/10.1021/acs.jmedchem.0c02085.s002Test

المؤلفون: Malcolm P. Huestis (10493092), Darlene Dela Cruz (10493095), Antonio G. DiPasquale (1274730), Matthew R. Durk (7052600), Charles Eigenbrot (1346406), Paul Gibbons (114343), Alberto Gobbi (1508113), Thomas L. Hunsaker (3160575), Hank La (438084), Dennis H. Leung (2106256), Wendy Liu (2057074), Shiva Malek (1346394), Mark Merchant (282025), John G. Moffat (413533), Christine S. Muli (10493098), Christine J. Orr (10493101), Brendan T. Parr (2342548), Frances Shanahan (655624), Christopher J. Sneeringer (10493104), Weiru Wang (640332), Ivana Yen (1346373), Jianping Yin (557395), Michael Siu (1503160), Joachim Rudolph (1464982)

مصطلحات موضوعية: Biophysics, Biochemistry, Medicine, Cell Biology, Molecular Biology, Pharmacology, Cancer, Hematology, Infectious Diseases, Virology, Space Science, Chemical Sciences not elsewhere classified, Physical Sciences not elsewhere classified, kinase selectivity, vivo evaluation, solubility, Combination Treatment, MEK inhibitor cobimetinib, tumor growth inhibition, NH functionality, pathway inhibition, Strategic substitution, fluoroquinazolinone hinge-binding motif, xenograft mouse model, C 5 position, RAF-specific residue interactions, aryl urea RAF inhibitors, type II pan-RAF inhibitor GNE -0749, Targeting KRAS Mutant Cancers

العلاقة: https://figshare.com/articles/dataset/Targeting_KRAS_Mutant_Cancers_via_Combination_Treatment_Discovery_of_a_5_Fluoro-4-_3_i_H_i_quinazolinone_Aryl_Urea_pan-RAF_Kinase_Inhibitor/14336950Test

الإتاحة: https://doi.org/10.1021/acs.jmedchem.0c02085.s003Test

المؤلفون: Malcolm P. Huestis (10493092), Matthew R. Durk (7052600), Charles Eigenbrot (1346406), Paul Gibbons (114343), Thomas L. Hunsaker (3160575), Hank La (438084), Dennis H. Leung (2106256), Wendy Liu (2057074), Shiva Malek (1346394), Mark Merchant (282025), John G. Moffat (413533), Christine S. Muli (10493098), Christine J. Orr (10493101), Brendan T. Parr (2342548), Frances Shanahan (655624), Christopher J. Sneeringer (10493104), Weiru Wang (640332), Ivana Yen (1346373), Jianping Yin (557395), Joachim Rudolph (1464982), Michael Siu (1503160)

مصطلحات موضوعية: Biochemistry, Medicine, Cell Biology, Molecular Biology, Pharmacology, Developmental Biology, Cancer, Infectious Diseases, Virology, Chemical Sciences not elsewhere classified, Information Systems not elsewhere classified, Pyridopyridazinone pan-RAF Kinase I., kinase-selective RAF inhibitors, HCT 116 xenograft mouse model, Targeting KRAS Mutant Cancers, MEK inhibitor cobimetinib, Type II pan-RAF inhibitor GNE -9815, GNE -9815, MAPK pathway modulation, aryl urea RAF inhibitors

العلاقة: https://figshare.com/articles/journal_contribution/Targeting_KRAS_Mutant_Cancers_via_Combination_Treatment_Discovery_of_a_Pyridopyridazinone_pan-RAF_Kinase_Inhibitor/14460218Test

الإتاحة: https://doi.org/10.1021/acsmedchemlett.1c00063.s001Test